Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Corporate Update (January 2008)
9 slides from Novo Nordisk A/s Class B's corporate update, Jan 15, 2008
Slide 1: Conference call - refocusing inhaled insulin activities
Conference call A focused healthcare company Conference call - refocusing inhaled insulin activities 15 January 2008, 10.00 CET, 09.00 UK time, 4.00 New York time
Slide 2: Agenda
Conference call R&D activities within inhaled insulin Slide no 1 Agenda • Introduction Jesper Brandgaard, CFO • Refocusing R&D activities within inhaled insulin Mads Krogsgaard Thomsen, CSO • Financial implications Jesper Brandgaard, CFO • Questions & answers
Slide 3: Forward-looking statements
Conference call R&D activities within inhaled insulin Slide no 2 Forward-looking statements The above contains forward-looking statements as the term is defined in the US Private Securities Litigation Reform Act of 1995. This in particular relates to information included under the headings ‘Outlook
Slide 4: Review of the medical and commercial potential for inhaled insulin
Conference call R&D activities within inhaled insulin Slide no 3 Review of the medical and commercial potential for inhaled insulin • Limited clinical and convenience benefits of current generation of fast-acting inhaled insulin • Unlikely to offer significant clinical or convenience benefits over i
Slide 5: Discontinuation of AERx
Conference call R&D activities within inhaled insulin Slide no 4 Discontinuation of AERx® • Decision not due to safety concerns • Termination of clinical development and manufacturing activities of AERx® devices and insulin strips • Significant number of employees at Novo Nordisk’s site in Hayward,
Slide 6: Refocus of R&D activities within inhaled insulin
Conference call R&D activities within inhaled insulin Slide no 5 Refocus of R&D activities within inhaled insulin • Focus on new generation of devices for pulmonary administration • inhalation systems for long-acting insulin and GLP-1 • liquid-based and powder-based technologies • more convenient de
Slide 7: Financial implications
Conference call R&D activities within inhaled insulin Slide no 6 Financial implications • A non-recurring cost of around DKK 1.3 billion in 2007 • around DKK 900 million related to write-down and impairment of tangible and intangible assets • around DKK 300 million related to discontinuation of clin
Slide 8: Concluding remarks
Conference call R&D activities within inhaled insulin Slide no 7 Concluding remarks • Termination of clinical development of AERx® • limited clinical and convenience benefits • Unlikely to offer significant clinical or convenience benefits over injection devices such as FlexPen® • Decision not due t
Slide 9: Investor information
Conference call R&D activities within inhaled insulin Slide no 8 Investor information Share information Investor Relations Novo Nordisk’s B shares are listed contacts on the stock exchanges in Novo Nordisk A/S Investor Relations Copenhagen and London. Its ADRs Novo Allé, DK-2880 Bagsværd are listed